Biotechnology company · JAZZ

Jazz Pharmaceuticals
clinical trial
pipeline

Registry checked

Published

Zanidatamab is linked to 6 distinct active studies, with 2 Phase 2, 3 Phase 3, 1 without a recorded phase. JZP3507 is linked to 3 distinct active studies, with 1 Phase 1, 2 Phase 2.

Phase 2 study NCT06695845 in Breast Cancer and Gastric Cancer lists estimated primary completion on 31 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

25active trials
as lead sponsor
  • Phase 16
  • Phase 26
  • Phase 37
  • Phase 42
  • Phase not recorded4

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

54 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later

2026-07 (estimated)2027-03-31 (estimated)
Jul 202631 Mar 2027

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

NCT04541082 · ClinicalTrials.gov
Recorded by ComplyRx
23 Oct 2026
Registry last updated
23 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000111
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-071000011
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-231200032
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals2200154 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Zanidatamab

ziihera

6
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 22
  • Phase 33
  • Phase 40
  • Phase not recorded1
Studied condition
Biliary Tract Cancer · Breast Cancer · Colorectal Cancer
Next primary completion
31 December 2026 · estimated
Open drug

JZP3507

Canonical investigational asset

3
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Pheochromocytoma and Paraganglioma · Anaplastic Astrocytoma · Anaplastic Meningioma
Next primary completion
Not reported
Open drug

Cannabidiol

Canonical investigational asset

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 42
  • Phase not recorded0
Studied condition
Dravet Syndrome · Lennox Gastaut Syndrome · Lennox-Gastaut Syndrome
Next primary completion
Not reported
Open drug

CBD-OS

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Developmental and Epileptic Encephalopathy (DEE) · Focal Seizures
Next primary completion
Not reported
Open drug

Lurbinectedin

zepzelca

2
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Ewing Sarcoma · Extensive-stage Small-cell Lung Cancer · Refractory Ewing Sarcoma
Next primary completion
Not reported
Open drug

Dordaviprone

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Glioma · H3 K27M
Next primary completion
Not reported
Open drug

19 of 25 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 19 of 25 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Jazz Pharmaceuticals trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Zanidatamab

NCT06695845

Phase 2 · Recruiting

Trial source and qualifications

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 14 Jan 2025 · actual
    Primary completion: 31 Dec 2026 · estimated
    Study completion: 31 Dec 2027 · estimated

    2021202220232024202520262027202820292030
    XYRISE
    Asset mapping not recorded

    NCT07625280

    Phase 3 · Recruiting

    Trial source and qualifications

    A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    No eligible observations recorded in the inspected period.

      Start: 09 Jul 2026 · actual
      Primary completion: 23 Dec 2027 · estimated
      Study completion: 06 Jan 2028 · estimated

      2021202220232024202520262027202820292030
      EmpowHER 208
      Zanidatamab

      NCT07102381

      Phase 2 · Recruiting

      Trial source and qualifications

      A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 24 Sept 2025 · actual
        Primary completion: 29 Dec 2027 · estimated
        Study completion: 02 May 2030 · estimated

        2021202220232024202520262027202820292030
        Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
        Lurbinectedin

        NCT05734066

        Phase 2 · Recruiting

        Trial source and qualifications

        Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 23 May 2023 · actual
          Primary completion: 28 Jan 2028 · estimated
          Study completion: 20 Apr 2028 · estimated

          2021202220232024202520262027202820292030
          A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
          Lurbinectedin

          NCT07459634

          Phase 2 · Recruiting

          Trial source and qualifications

          A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          1 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 1 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 30 Nov 2026 · estimated
            Primary completion: 31 Jan 2028 · estimated
            Study completion: 30 Apr 2028 · estimated

            2021202220232024202520262027202820292030
            A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
            Zanidatamab

            NCT06435429

            Phase 3 · Recruiting

            Trial source and qualifications

            A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

            Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

            1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

            ClinicalTrials.gov source

            1 inspected observations omitted. At most three verified observations are shown, not full history.

              Start: 13 Aug 2024 · actual
              Primary completion: 28 Apr 2028 · estimated
              Study completion: 18 Oct 2030 · estimated

              2021202220232024202520262027202820292030

              Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

              6 selected of 12 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 1 actual primary completions, 0 untyped primary completions, 0 past estimates, 0 outside the horizon, 0 contradictory dates.

              04 / Therapeutic focus

              Where the activity is

              13

              active trials in Oncology

              Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

              Active trials by primary therapeutic area

              • Oncology13 trials
              • Neurology4 trials
              • Genetic & Rare Disease1 trials
              • Unmapped5 trials
              • Healthy volunteers2 trials

              Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

              06 / Related companies

              All companies

              Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

              Sources, scope and methodology

              ClinicalTrials.gov lead-sponsor scope

              Canonical current-owner attribution covers 220 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Jazz Pharmaceuticals. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

              ClinicalTrials.gov

              Attribution coverage

              220 distinct registry candidates produced 220 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

              Indexed enrichment

              196 scoped records have indexed enrichment and 24 do not. Missing enrichment does not remove a trial from cohort counts.

              Scope observation

              The successful attribution check completed at 2026-11-01T05:22:48.497Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot f648e22f325f75247affde32ce80b2b37c18672d0c51aac72dda258914e86da6.

              Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

              Dated canonical-attribution snapshot: 220 mapped lead-sponsored clinical studies across all statuses. 196 have indexed enrichment, 24 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

              Keep following
              what matters.

              Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

              Build your watch

              Choose what to track in the watch builder.